| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Molecular Physiology and Biological Physics,
Center for Cellular Signaling,
Department of Radiation Oncology,
|| Department of Health Evaluation Sciences, University of Virginia, Charlottesville, Virginia, USA; and
American Institute for Diseases of the Prostate, Charlottesville, Virginia, USA
1Correspondence: Department of Molecular Physiology and Biological Physics, University of Virginia, 1300 Jefferson Park Ave., P.O. Box 800736, Jordan Hall, Charlottesville, VA 22908-0736, USA. E-mail: avs5u{at}virginia.edu or aps2n{at}virginia.edu
The purpose of this study was to determine the effects of inhibitors of Rho kinase (ROK) and matrix metalloproteinases (MMPs) on angiogenesis and tumor growth and to evaluate ROK activity in human prostate cancer PC3 cells and endothelial cells (HUVECs). Vacuolation by endothelial cells and lumen formation, the earliest detectable stages of angiogenesis, were inhibited by the ROK inhibitor Wf-536. Combining Wf-536 with the MMP inhibitor Marimastat greatly enhanced in vitro inhibition of endothelial vacuolation, lumen and cord formation, and VEGF- and HGF-stimulated endothelial sprout formation from aorta. Inhibition of sprout formation by the two inhibitors was synergistic. Both agents inhibited migration of HUVECs. The regulatory subunit (MYPT1) of the myosin phosphatase was phosphorylated in PC3 cells and HUVECs, and phosphorylation of MYPT1 and the myosin regulatory light chain was reduced by Wf-536, providing direct evidence of ROK activity. Early treatment of immuno-incompetent mice bearing xenotransplants of PC3 cells with a combination of Wf-536 plus Marimastat with or without Paclitaxel, significantly inhibited tumor growth, prevented tumor growth escape after discontinuation of Paclitaxel, and increased survival.—Somlyo, A. V., Phelps, C., Dipierro, C., Eto, M., Read, P., Barrett, M., Gibson, J. J., Burnitz, M. C., Myers, C., Somlyo, A. P. Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.
Key Words: myosin phosphatase • G-protein • endothelium • tumor necrosis
This article has been cited by other articles:
|
|
 |
|
  E. Roudier, N. Chapados, S. Decary, C. Gineste, C. Le Bel, J.-M. Lavoie, R. Bergeron, and O. Birot Angiomotin p80/p130 ratio: a new indicator of exercise-induced angiogenic activity in skeletal muscles from obese and non-obese rats? J. Physiol., August 15, 2009; 587(16): 4105 - 4119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. De Smet, I. Segura, K. De Bock, P. J. Hohensinner, and P. Carmeliet Mechanisms of Vessel Branching: Filopodia on Endothelial Tip Cells Lead the Way Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 639 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. van Nieuw Amerongen and V. W. M. van Hinsbergh Role of ROCK I/II in vascular branching Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H903 - H905. [Full Text] [PDF]
|
|
|
|
|
|
J. Kroll, D. Epting, K. Kern, C. T. Dietz, Y. Feng, H.-P. Hammes, T. Wieland, and H. G. Augustin Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H893 - H899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mizuno, E. Isotani, J. Huang, H. Ding, J. T. Stull, and K. E. Kamm Myosin light chain kinase activation and calcium sensitization in smooth muscle in vivo Am J Physiol Cell Physiol, August 1, 2008; 295(2): C358 - C364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-L. Lin, A. Chiang, D. Chang, and S.-Y. Ying Loss of mir-146a function in hormone-refractory prostate cancer RNA, March 1, 2008; 14(3): 417 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-L. Lin, D. Chang, A. Chiang, and S.-Y. Ying Androgen receptor regulates CD168 expression and signaling in prostate cancer Carcinogenesis, February 1, 2008; 29(2): 282 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yin, K.-i. Morishige, T. Takahashi, K. Hashimoto, S. Ogata, S. Tsutsumi, K. Takata, T. Ohta, J. Kawagoe, K. Takahashi, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo Mol. Cancer Ther., May 1, 2007; 6(5): 1517 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Marshall Rho Family GTPase Signaling in Tumor Cell Movement and Angiogenesis Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 103 - 108. [Full Text] [PDF]
|
|
|
|
|
|
S.-L. Lin, D. Chang, and S.-Y. Ying Hyaluronan stimulates transformation of androgen-independent prostate cancer Carcinogenesis, February 1, 2007; 28(2): 310 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Sandquist, K. I. Swenson, K. A. DeMali, K. Burridge, and A. R. Means Rho Kinase Differentially Regulates Phosphorylation of Nonmuscle Myosin II Isoforms A and B during Cell Rounding and Migration J. Biol. Chem., November 24, 2006; 281(47): 35873 - 35883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gorenne, L. Jin, T. Yoshida, J.M. Sanders, I.J. Sarembock, G.K. Owens, A.P. Somlyo, and A.V. Somlyo LPP Expression During In Vitro Smooth Muscle Differentiation and Stent-Induced Vascular Injury Circ. Res., February 17, 2006; 98(3): 378 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Hyvelin, K. Howell, A. Nichol, C. M. Costello, R. J. Preston, and P. McLoughlin Inhibition of Rho-Kinase Attenuates Hypoxia-Induced Angiogenesis in the Pulmonary Circulation Circ. Res., July 22, 2005; 97(2): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-J. Su, C. N. Hahn, G. J. Goodall, N. M. Reck, A. F. Leske, A. Davy, G. Kremmidiotis, M. A. Vadas, and J. R. Gamble A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesis PNAS, August 17, 2004; 101(33): 12212 - 12217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. N. Ye, E. S. L. Liu, V. Y. Shin, W. K. K. Wu, J. C. Luo, and C. H. Cho Nicotine Promoted Colon Cancer Growth via Epidermal Growth Factor Receptor, c-Src, and 5-Lipoxygenase-Mediated Signal Pathway J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 66 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. SOMLYO and A. V. SOMLYO Ca2+ Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase Physiol Rev, October 1, 2003; 83(4): 1325 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Gorenne, R. K. Nakamoto, C. P. Phelps, M. C. Beckerle, A. V. Somlyo, and A. P. Somlyo LPP, a LIM protein highly expressed in smooth muscle Am J Physiol Cell Physiol, September 1, 2003; 285(3): C674 - C685. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
